Back to Top

Osimertinib

0 comments

Submitted by Annemieke DeMaggio on Thu, 07/30/2020 - 10:15

Osimertinib granted FDA BTD for adjuvant treatment of resectable, EGFRmut NSCLC

Interim analysis of the phase 3 ADAURA study showed a significant improvement in DFS, and study was unblinded early in April 2020 (AZ press release)